After treatment with BRAF/MEK inhibitors, melanoma cells lacking GSDME exhibited impaired infiltration of tumor-associated T cells, the number of activated dendritic cells was diminished, and a higher incidence of tumor regrowth after cessation of drug treatment was recorded [74]. The gene discussed is BRAF; the disease is neoplasm.